PTPA and acute myeloid leukemia: Although whether EF-24 can prevent SET/PP2A-C binding needs to be further addressed, our current study showed that the PP2A inhibitor, OA, can reverse 2 μM EF-24-induced ERK deactivation, suggesting that high concentrations of EF-24 can suppress ERK activation via activating PP2A in HL-60 AML cells.